The notion of oxidative stress has changed over the past decades from the idea of being a phenomenon involved exclusively with oxidative damage to a more contemporary concept that includes its role in intracellular signaling pathways. Reactive oxygen species (ROS) such as superoxide anion (O 2 • − ), hydroxyl radical (OH • ), and hydrogen peroxide (H 2 O 2 ) can be generated by different intracellular sources such as NAD(P)H oxidase, xanthine oxidase, myeloperoxidase, and uncoupled nitric oxide synthase [1] . ROS are capable of reacting with several cellular components, resulting in lipid peroxidation, and damage to proteins and DNA. In order to counterregulate these oxidative processes, cells have developed enzymatic and nonenzymatic antioxidant systems that can offer protection by regulating antioxidant response element signaling pathways [2] . In this regard, some phytochemicals, such as sulforaphane, brazilin, chalcone, resveratrol, and curcumin, are reported to modulate translocation and activation of the nuclear factor-erythroid-2-related factor (Nrf2) and regulate antioxidant response [3] . The primary aim of this special issue is to highlight the central role of antioxidants in various experimental models of heart failure and endothelial dysfunction as well as in human studies.
This special issue contains a review article and primary research articles covering a broad range of topics related to the therapeutic potential of antioxidants in heart failure.
In a study by Y. Wang et al., sulforaphane attenuation of type-2 diabetes induced aortic fibrosis was associated with the upregulation of Nrf2 expression and function in mice. In another interesting study by M. H. Lee et al., resveratrol inhibited rat aortic vascular smooth muscle cell proliferation, dedifferentiation, and phenotype modulation. This finding was attributed to a differential regulation of prosurvival pathways by resveratrol, reinforcing the protective role of flavonoids by altering the phosphorylation state of some targeted molecules. Another polyphenol covered in this special issue is methyl gallate and its ability to afford cardioprotection against cobalt or H 2 O 2 -induced oxidative stress. This polyphenol was able to scavenge ROS, safeguarding mitochondria and cellular DNA and inhibiting the intrinsic apoptotic pathway.
Apoptosis is an important element of the cardiac remodeling process [4] . Suppression of apoptosis is a key target in attenuating adverse remodeling process [5] . In a related article featured in this special issue, a microRNA (miRNA) that targets glutathione peroxidase was utilized to explore its potential cardioprotective role against oxidative stressinduced apoptosis. This miRNA was markedly upregulated in apoptotic cells and its downregulation reduced the mitochondrial apoptotic pathway in cardiomyocytes exposed to oxidative stress. These novel findings may have some therapeutic Estrogen therapy as another antioxidant strategy is explored by two articles featured in this issue. The influence of estrogen on coronary resistance was studied by P. C. Schenkel et al. where they investigated the modulatory role of nitric oxide and H 2 O 2 levels in female rats. The data suggest that, in the absence of estrogen, coronary resistance regulation seems to be more dependent on H 2 O 2 which is maintained at low levels by increased catalase activity. The data provides a new insight regarding the role of oxidative stress balance in the regulation of coronary tone. One compelling question that is always raised regarding estrogen therapy is the optimal dose that should be used. An interesting paper by C. Campos et al. indicates that a low dose of estrogen (40% less than the pharmacological dose) was just as effective as a high dose for promoting improvement in cardiovascular function and reducing oxidative stress, thereby supporting the approach of using low dose of estrogen in clinical settings to minimize the risks associated with estrogen therapy.
The cardioprotective role of thyroid hormones has also been featured in this special issue. Administration of this hormone has been associated with increased ROS, Nrf2, thioredoxin, and heme-oxygenase levels in cardiac tissue [6] . It seems that a thyroid hormone-dependent counterregulatory response could represent a hormetic effect, in order to stabilize redox environment and provide cell survival [7] . An elegant review by C. Pantos and I. Mourouzis highlights the role of thyroid hormones in ischemia/reperfusion injury and the conversion from pathologic to physiologic growth after myocardial infarction via TR 1 receptor.
In summary, this special issue covers a wide range of topics addressing the role of oxidative stress and antioxidants in the pathophysiology of heart failure. These articles not only enrich our understanding of how oxidative stress plays an important role in heart failure but also provide evidence on antioxidant therapies in this condition.
